William Wesson

Medical student at the University of Kansas School of Medicine. Interested in hematology oncology and cellular therapy.

[William Wesson @wwesson24]

Thrilled that KU's work on CAR T safety and monitoring is gaining traction! Balancing Cures and Complications With CAR T-Cell Therapy https://t.co/zWlo4ydUnS via @TargetedOnc @NausheenAhmedMD @Abdallah81MD @DrAliyaRashid @KUIMchiefs

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

The Glass Wall: Gendered authorship disparities in CD 19 and BCMA CAR-T Clinical Trials for lymphoma and myeloma
Out there by upcoming superstar @aroogkhaliq mentored by #USMIRC academy director @NausheenAhmedMD and @mumairmushtaq @leshune @MediHumdani @JoaquinaBaranda #mmsm #myeloma #MedEd @OncoAlert @USMIRCNEWS

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias https://t.co/uOuHYzj38O by @wwesson24 @NausheenAhmedMD @leshune @hhashmi87 @thisisJamesD #Cart #USMIRC @USMIRCNEWS #MedTwitter #MedEd @OncoAlert #mmsm @KUcancercenter

[Nausheen Ahmed MD @NausheenAhmedMD]

#ASH23 posters. CAR-T therapy comes with a 4⃣week monitoring for CRS/ICANS. is a flexible monitoring period possible? Why is that important to evaluate? 'cuz relocating has ⬆️ financial/physical burden on pts, ⬆️ #disparities #access #CART #lymsm